Ascendis Pharma Presented One-Year P-III Trial (PaTHway) Results of TransCon PTH for Hypoparathyroidism at ENDO 2023
Shots:
- The P-III trial evaluating TransCon PTH in adults, showed sustained improvements through 52wk. as well as safety & tolerability similar to that reported for the initial 26wk. blinded portion of the trial
- 95% of patients in the OLE achieved independence from conventional therapy & none required active vitamin D; normal serum calcium & independence from conventional therapy (81%); mean albumin-adjusted serum calcium levels were maintained within the normal range through 52wk. of the OLE (8.9mg/dL)
- Improved mean patient-reported disease symptom & health-related QoL scores starting at 1st scheduled follow-up after randomization or switching from PBO & sustained @52wk., BMD Z-scores continued to trend toward age & sex-matched norms @52wks., normalized 24hr. urine calcium regardless of initial randomization, was well-tolerated with no new safety signal
Ref: Globenewswire | Image: Ascendis Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
